Free Access
Med Sci (Paris)
Volume 32, Number 8-9, Août–Septembre 2016
Page(s) 690 - 692
Section Nouvelles
Published online 12 September 2016
  1. Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014 ; 32 : 659–702. [CrossRef] [PubMed] [Google Scholar]
  2. Jacquelot N, Roberti MP, Enot DP, et al. Immunophenotyping of stage III melanoma reveals parameters associated with patient prognosis. J Invest Dermatol 2016 ; 136 : 994–1001. [CrossRef] [PubMed] [Google Scholar]
  3. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011 ; 11 : 597–606. [CrossRef] [PubMed] [Google Scholar]
  4. Salerno EP, Olson WC, McSkimming C, et al. T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer 2014 ; 134 : 563–574. [CrossRef] [PubMed] [Google Scholar]
  5. Jacquelot N, Enot DP, Flament C, et al. Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest 2016 ; 126 : 921–937. [PubMed] [Google Scholar]
  6. Mullins IM, Slingluff CL, Lee JK, et al. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 2004 ; 64 : 7697–7701. [CrossRef] [Google Scholar]
  7. Kato M, Takahashi M, Akhand AA, et al. Transgenic mouse model for skin malignant melanoma. Oncogene 1998 ; 17 : 1885–1888. [CrossRef] [PubMed] [Google Scholar]
  8. Perez-Chanona E, Trinchieri G. The role of microbiota in cancer therapy. Curr Opin Immunol 2016 ; 39 : 75–81. [CrossRef] [PubMed] [Google Scholar]
  9. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 ; 363 : 711–723. [CrossRef] [PubMed] [Google Scholar]
  10. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011 ; 364 : 2517–2526. [Google Scholar]
  11. Tartour E, Sandoval F, Bonnefoy JY, Fridman WH. Immunothérapie des cancers : Succès récents et perspectives. Med Sci (Paris) 2011 ; 27 : 833–841. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Fecher LA, Agarwala SS, Hodi FS, Weber JS. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013 ; 18 : 733–743. [CrossRef] [PubMed] [Google Scholar]
  13. Teillaud JL. Microenvironnements tumoraux : conflictuels et complémentaires. Med Sci (Paris) 2014 ; 30 : 343–462. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.